Gujral told CNBC-TV18, "Pharma generally have done well and Nectar Lifesciences has had good last three days. So I think if it can stay above Rs 340 I think levels of Rs 440-445 are possible."
Disclosure: It is safe to assume that analyst and his clients may have an investment interest in the above stock/sector.
